Acute myeloid leukemia, NPM1-mutated

From - A Hematology Oncology Wiki
Jump to: navigation, search
Section editor
Martin W. Schoen, MD, MPH
Saint Louis University
St. Louis, MO

Social-twitter-icon.png mwschoen

Note: these are regimens tested in biomarker-specific populations for patients with NPM1-mutated AML, please see the main AML page for other regimens.

1 regimens on this page
1 variants on this page


"How I Treat"

Upfront induction therapy


back to top

ICE & ATRA: Idarubicin, Cytarabine, Etoposide, All-Trans Retinoic Acid


Study Years of enrollment Evidence Comparator Comparative Efficacy
Schlenk et al. 2019 (AMLSG 09-09) 2010-2017 Phase III (C) ICE, ATRA, GO Did not meet primary endpoint of EFS

To be completed


Targeted therapy


  1. AMLSG 09-09: Schlenk RF, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik VI, Leis C, Fiedler W, Kindler T, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Horst HA, Koller E, Wulf G, Schleicher J, Bentz M, Greil R, Hertenstein B, Krauter J, Martens U, Nachbaur D, Abu Samra M, Girschikofsky M, Basara N, Benner A, Thol F, Heuser M, Ganser A, Döhner K, Döhner H. Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. J Clin Oncol. 2020 Feb 20;38(6):623-632. Epub 2019 Dec 18. link to original article PubMed